News Release

Cidara Therapeutics Announces Formation of Scientific Advisory Board

July 27, 2020 at 8:00 AM EDT
Comprised of World-Renowned Experts in Virology, Fungal Diseases and Hematology

SAN DIEGO, July 27, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing serious fungal or viral infections, today announced the formation of a scientific advisory board (SAB) and the appointment of four leading experts in viral and fungal infections and hematology. The SAB will work closely with the Cidara management team to help guide the direction and design of the company’s development programs with an emphasis on the continued development and expansion of the company’s Cloudbreak Antiviral Conjugate (AVC) program.

“We are proud to have globally recognized key opinion leaders in virology, fungal diseases, transplant and hematology joining our newly formed SAB,” said Jeffrey Stein, Ph.D., president and chief executive officer of Cidara. “The SAB members’ collective expertise aligns with the advancement of our Cloudbreak antiviral conjugates into respiratory viruses such as influenza, RSV and coronavirus as well as with potential additional applications of rezafungin for the prevention of fungal infections in patients with hematologic malignancies and for Covid Associated Pulmonary Aspergillosis (CAPA).”

Cidara Therapeutics’ SAB is comprised of:

  • Frederick G. Hayden, MD, FACP, Stuart S. Richardson Professor Emeritus of Clinical Virology at University of Virginia School of Medicine; Professor Emeritus of Medicine at University of Virginia, Charlottesville, VA
     
  • Michael G. Ison, MD, MS, FIDSA, FAST, Professor, Divisions of Infectious Diseases and Organ Transplantation at Northwestern University Feinberg School of Medicine; Medical Director, Transplant & Immunocompromised Host Infectious Diseases Service   at Northwestern University Comprehensive Transplant Center, Chicago, IL
     
  • Johan A Maertens, MD, PhD, FECCM, Professor of Internal Medicine and Hematology, Acute Leukemia and Transplantation Unit at University Hospitals Leuven; Department of Microbiology, Immunology and Transplantation at KULeuven, Leuven, Belgium
     
  • Kieren Marr, MD, MBA, Professor of Medicine and Oncology Director, Transplant and Oncology Infectious Diseases Program and Vice Chair for Innovation in Healthcare Implementation, Department of Medicine at Johns Hopkins University School of Medicine, Baltimore, MD

About Cidara Therapeutics
Cidara is developing long-acting therapeutics to improve the standard of care for patients facing serious fungal or viral infections. The Company’s portfolio is comprised of breakthrough approaches aimed at transforming existing treatment and prevention paradigms, first with its lead antifungal candidate, rezafungin, in addition to antiviral conjugates (AVCs) targeting influenza and other viral diseases from Cidara’s proprietary Cloudbreak® antiviral platform. Cidara is headquartered in San Diego, California. For more information, please visit www.cidara.com.

INVESTOR CONTACT:
Brian Ritchie
LifeSci Advisors
(212) 915-2578
britchie@lifesciadvisors.com

MEDIA CONTACT:
Karen O’Shea, Ph.D.
LifeSci Communications
(929) 469-3860
koshea@lifescicomms.com


CidaraLogo (1).jpg

Source: Cidara Therapeutics, Inc.